FLT3-TAZ Signaling Drives Drug Resistance in Blast Phase CML: Insights from Shin et al. (2023)

Study Background and Research Question

Chronic myeloid leukemia (CML) is characterized by the BCR::ABL1 fusion kinase, a molecular driver that has been successfully targeted by tyrosine kinase inhibitors (TKIs), transforming CML into a largely manageable disease. However, a subset of patients progress to advanced stages, notably blast phase CML (BP-CML), where resistance to TKIs and poor outcomes remain critical challenges. While BCR::ABL1 mutations are a known resistance mechanism, accumulating evidence suggests that kinase-independent pathways also play a substantial role. Shin et al. (2023) sought to identify alternative drivers of drug resistance in BP-CML and evaluate whether these could be effectively targeted to improve therapeutic outcomes (Shin et al., 2023).

Key Innovation from the Reference Study

The central innovation of the study is the identification and mechanistic dissection of FLT3 (FMS-like tyrosine kinase 3) as a pivotal driver of drug resistance in BP-CML. Traditionally recognized for its role in acute myeloid leukemia (AML), FLT3 is repositioned here as both a prognostic biomarker and a therapeutic target in BP-CML. The authors delineate a distinct subgroup of BP-CML patients with elevated FLT3 expression (FLT3+ BP-CML), who display markedly inferior prognoses compared to their FLT3− counterparts. Crucially, the study demonstrates that FLT3-driven resistance operates independently of canonical BCR::ABL1 mutations, highlighting a new axis of resistance rooted in the FLT3-JAK-STAT3-TAZ-TEAD-CD36 signaling cascade (Shin et al., 2023).

Methods and Experimental Design Insights

Shin et al. combined multi-omics analyses, in vitro cellular assays, and in vivo mouse models to interrogate the role of FLT3 signaling in BP-CML. The study employed the following methodological strategies:

• Generated BCR::ABL1 TKI-resistant CML cell lines with forced FLT3 expression to model resistance mechanisms.
• Analyzed patient-derived samples from a phase-specific CML cohort, including serial specimens from chronic, accelerated, and blast phases, to correlate FLT3 protein expression and localization with clinical outcomes.
• Utilized phosphoproteomics and transcriptomics to elucidate the downstream signaling networks associated with FLT3 activation.
• Tested the efficacy of FLT3 inhibitors, both alone and in combination with BCR::ABL1 TKIs (including ponatinib and midostaurin), using patient-derived FLT3+ BP-CML cells and murine xenograft models.

This comprehensive approach enabled the authors to link FLT3 activity to resistance phenotypes and to probe the therapeutic potential of FLT3-targeted intervention.

Protocol Parameters

• FLT3 autophosphorylation inhibition assay | IC50: 1.1 nM (ITD), 4.2 nM (WT) | In vitro evaluation of FLT3 inhibitors in AML and BP-CML models | Enables high-sensitivity assessment of FLT3 pathway blockade | product_spec
• In vivo FLT3 inhibition in mouse xenograft models | Oral dose: ≥1 mg/kg | Preclinical validation of FLT3-targeted therapies | Recapitulates FLT3-driven disease and assesses therapeutic efficacy | product_spec
• Patient sample FLT3 protein expression analysis | Immunoblotting/IHC; standardized scoring | Diagnostic stratification of BP-CML subgroups | Correlates FLT3 status with prognosis and therapy selection | paper
• FLT3 signaling pathway activity profiling | Phosphoproteomics; pathway enrichment | Mechanistic investigation in multi-omics studies | Identifies actionable FLT3-driven networks in resistant CML | paper
• FLT3 inhibitor + BCR::ABL1 TKI combination therapy | Workflow-optimized dosing per cell model | Research recommendation for resistance studies | Empirically overcomes FLT3-mediated TKI resistance | workflow_recommendation

Core Findings and Why They Matter

The study’s most consequential finding is that FLT3 expression in BP-CML confers resistance to a broad spectrum of BCR::ABL1 TKIs, independent of mutations in the BCR::ABL1 kinase domain. Mechanistically, FLT3 activates a downstream JAK-STAT3-TAZ-TEAD-CD36 pathway, promoting survival and persistence of leukemic cells despite TKI therapy. Notably, FLT3+ BP-CML patients exhibited significantly reduced overall survival compared to FLT3− patients, positioning FLT3 as a clinically relevant prognostic marker.

Therapeutic targeting of FLT3—either by combining FLT3 inhibitors with BCR::ABL1 TKIs or by using single agents such as ponatinib—restored sensitivity and induced cell death in resistant BP-CML models. These results were validated in patient-derived cells and in vivo, where FLT3 inhibition effectively suppressed leukemic cell growth (Shin et al., 2023).

Comparison with Existing Internal Articles

Several internal reviews have covered the role of FLT3 inhibitors, particularly Quizartinib (AC220), in acute myeloid leukemia (AML) research. For instance, one analysis describes the nanomolar selectivity of Quizartinib for FLT3 and its robust application in kinase inhibition and resistance modeling. Another review explores novel assay strategies and emerging resistance in AML preclinical studies. However, Shin et al. (2023) extend these insights into BP-CML, a domain where FLT3 was previously underappreciated as a therapeutic target. The cross-domain application of FLT3 inhibitors—originally developed for AML—into BP-CML models underscores a novel therapeutic strategy that leverages molecular similarities between these malignancies. This is further echoed in an internal thought-leadership article advocating for translational use of FLT3 inhibitors to overcome therapeutic resistance in both AML and BP-CML, in line with the findings of Shin et al. (Shin et al., 2023).

Limitations and Transferability

While Shin et al. provide compelling evidence for the role of FLT3 in BP-CML resistance, several limitations warrant consideration. First, the mechanistic studies predominantly focus on cell line and murine models, which may not fully recapitulate the complexity of human BP-CML. Second, while the multi-omics approach is powerful, validation in larger, prospectively collected patient cohorts is needed to confirm FLT3’s prognostic utility and therapeutic value. Finally, the potential for resistance mutations within FLT3 itself—already observed in AML—may limit the durability of FLT3-targeted strategies in CML and should be an area for future investigation (Shin et al., 2023).

Why this cross-domain matters, maturity, and limitations

The extension of FLT3 inhibition strategies from AML to BP-CML is grounded in mechanistic convergence—both malignancies can exhibit FLT3-driven signaling dependencies. This cross-domain approach is feasible due to the molecular parallels established in Shin et al. (2023), but its clinical maturity in BP-CML remains to be fully established. Limitations include a lack of large-scale clinical trial data in CML and possible emergence of FLT3 inhibitor resistance, already documented in AML (Shin et al., 2023).

Research Support Resources

Researchers aiming to investigate FLT3-driven resistance mechanisms in BP-CML or AML can utilize potent FLT3 inhibitors such as Quizartinib (AC220) (SKU A5793). Quizartinib offers high selectivity for both FLT3-ITD and wild-type FLT3, with validated activity in both cellular and in vivo models (source: product_spec). For detailed workflow recommendations and application strategies, refer to the referenced internal reviews and Shin et al. (2023). Please note that Quizartinib is intended for research use only and not for clinical or diagnostic applications.